Notice of Results

Summary by AI BETAClose X

Inspiration Healthcare Group plc announced that it will release its unaudited interim results for the six months ending 31 July 2026 on 27 October 2026. The company will host an analyst briefing at 09:30 GMT and a live investor presentation via the Investor Meet Company platform at 11:00 GMT on the same day, allowing shareholders to submit questions in advance or during the event.

Disclaimer*

Inspiration Healthcare Group PLC
09 October 2026
 

Inspiration Healthcare Group plc

(“Inspiration Healthcare”, the “Company” or the “Group”)

 

Notice of Results

Investor & analyst briefings

 

Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company, announces it will issue unaudited interim results for the six months ended 31 July 2026 on 27 October 2026.

 

Analyst briefing

A briefing open to equity research analysts will take place on 27 October 2026 at 09:30am GMT. To register and for more details please contact Walbrook PR on inspirationhealthcare@walbrookpr.com.

 

Investor presentation

Raffi Stepanian CEO, and Alan Olby CFO, will provide a live presentation relating to the results via the Investor Meet Company platform on 27 October 2026 at 11:00am GMT.  

 

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet Inspiration Healthcare.

To register for the presentation, please do so here.  

 

Investors who already follow Inspiration Healthcare on the Investor Meet Company platform will automatically be invited.

 

For further information, please contact:

 

Inspiration Healthcare Group plc

Tel: +44 (0)20 7496 3000

Raffi Stepanian, Chief Executive Officer

 

Alan Olby, Chief Financial Officer

 

 

 

Singer Capital Markets (Nominated Adviser & Broker)

Tel: +44 (0)20 7496 3000

Alex Bond

Graham Hertrich

 

Patrick Weaver

 

 

 

Cavendish Capital Markets (Joint Broker)

Tel: + 44 (0)20 7220 0500

Giles Balleny / Joe Smith

 

Nigel Birks

 

Harriet Ward

 

 

 

Walbrook PR Ltd (Media & IR)

Tel: +44 (0)20 7933 8780 or inspirationhealthcare@walbrookpr.com

Anna Dunphy

Mob: +44 (0) 7876 741 001

Rachel Broad

Mob: +44 (0) 7747 515 393

 


 

About Inspiration Healthcare

 

Inspiration Healthcare (AIM: IHC) designs, manufactures and markets pioneering medical technology. Based in the UK, the Company specialises in neonatal intensive care medical devices, which are addressing a critical need to help to save the lives and improve the outcomes of patients, starting with the very first breaths of life.

 

The Company has a broad portfolio of its own products and complementary distributed products, for use in neonatal intensive care designed to support even the most premature babies throughout their hospital stay. Its own branded products range from highly sophisticated capital equipment such as ventilators for life support through to single-use disposables.

 

The Company sells its products directly to hospitals and healthcare providers in the UK and Ireland, where it also distributes a range of advanced medical technologies for infusion therapy.  In the rest of the world the Company has an established network of distribution partners around the world giving access to more than 75 countries.

 

The Company operates in the UK from its world-class Manufacturing and Technology Centre in Croydon, South London and in the USA from its facility in Melbourne, Florida.

 

Further information on Inspiration Healthcare can be found at www.inspirationhealthcaregroup.com  

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings